This is an unrestricted procurement for Denosumab Injection (60MG and 120MG) to supply multiple federal agencies, including the VA and DoD. The contract will be for one base year plus four one-year option periods. The estimated annual usage is 22,737 units of the 60MG injection and 5,472 units of the 120MG injection. Products will be distributed through the VA and DoD Pharmaceutical Prime Vendor programs. Offerors must supply the drug under their own unique label and NDC number and must have specific pricing agreements in place with the VA to be considered.